Submission Deadline
09 Dec 2023 (Vol 46 , Iss 12 )

Upcoming Publication
31 Dec 2023 (Vol 46 , Iss 12 )

Journal ID : TMJ-25-11-2021-10825
Download [This article belongs to Volume - 44, Issue - 06]
Total View : 453


Abstract :

The COVID 19 pandemic of 2020 has killed an extra 1,800,000 people around the planet. Shortness of breath and fibrosis of the lungs are common side effects for people who recover with Covid-19, but others require a long time to recover. Idiopathic pulmonary fibrosis is a disease that can be treated with the medicine pirfenidone. Pirfenidone has been shown to reverse pulmonary fibrotic damage. There are five cases here where this medicine was added and showed a significant improvement in both symptoms and radiological results, which we discuss. This novel condition necessitates a thorough examination of the fraction of patients who develop chronic lung disease as a result of fibrosis following recovery from COVID-19. Pirfenidone should be studied further in people with pulmonary fibrosis due to Covid-19 infection to see if it helps. Methods verified COVID-19 patients admitted to al-Hindia general hospital between February 1, 2020, and August 1, 2020, were examined retrospectively for around six months. Pirfenidone was used to treat 13 incidences of lung fibrosis in 19 of the 107 patients who presented with covid symptoms. Idiopathic pulmonary fibrosis (IPF) was licensed as an anti-fibrotic drug in China in December 2013. Impairment of TGF-, CTGF, PDGF, and TNF- in inflammatory disorders is critical to the anti-fibrotic effect of pirfenidone. A severe hazard to the long-term prognosis of problems, pulmonary fibrosis, should also be considered. In the treatment of pulmonary fibrosis, pirfenidone may be the most successful medication COVID-19, pirfenidone, and Pulmonary fibrosis are all relevant terms.

Full article